Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy of Targeted Drugs Combined With Chemotherapy in the Treatment of T-ALL
Sponsor: Nanfang Hospital, Southern Medical University
Summary
This prospective, randomized, controlled trial evaluates the efficacy and safety of a new targeted drug combined with chemotherapy versus standard chemotherapy alone. Eligible patients were randomized 1:1 to either the treatment or control group.
Official title: Efficacy and Safety of Targeted Drugs Combined With Chemotherapy in the Treatment of Patients With Newly Diagnosed Acute T-lymphocytic Leukemia
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
154
Start Date
2025-10-01
Completion Date
2026-12-30
Last Updated
2025-10-02
Healthy Volunteers
No
Conditions
Interventions
targeted drug
Patients randomly assigned to the control group will receive standard chemotherapy treatment, but they cannot use targeted drugs in combination.The subjects randomly assigned to the experimental group received targeted drug treatment in addition to the chemotherapy regimen during the second course. Based on the results of bone marrow PCR, subjects with molecular typing of ABL1/ABL2/PDGFRB fusion were to receive chemotherapy combined with dasatinib 100mg orally once a day; subjects with molecular typing of FLT3-ITD positive were to receive chemotherapy combined with sorafenib 400mg orally twice a day.
Locations (1)
Department of Hematology,Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China